PACS Group Delivers Strong Second-Quarter Financials
PACS Group, Inc. reported a 9.1% increase in revenue and a 35.8% rise in operating profit for the second quarter of 2026, with net income reaching $76.3 million. The company demonstrated operational resilience, with same-store revenue growth of 5.8% across 284 nursing facilities operating since early 2025. Occupancy rates improved from 89.1% to 90.6%, and patient days rose by 2.2%. Skilled nursing patient proportion increased to 29.7%, while mature facilities maintained a robust occupancy rate of 93.8%. Newly acquired centers showed lower occupancy, reflecting their different operational stages.
Eduro Acquisition Presents Integration Hurdles and Revenue Opportunity
PACS recently completed the acquisition of 34 facilities under Eduro, covering 3,633 nursing beds. Of these, 20 facilities in Texas were closed on August 1, with the remaining 14 expected to finalize transfer by late fall or early winter. Management disclosed initial occupancy at around 60% in Eduro facilities with only 10% to 11% skilled nursing mix, indicating significant work needed to improve operations. Assuming a stabilized 75% occupancy and daily revenue of $475, annualized revenue for these facilities is projected at approximately $472 million. However, considering integration challenges and operational risks, the company models only $260 million in incremental contribution. PACS raised its 2026 revenue guidance to a range of $5.75 billion to $5.85 billion, with adjusted EBITDA forecast between $640 million and $660 million, implying nearly 29% year-over-year growth.
Valuation Snapshot: PACS vs. Ensign Group
Within the sector, Ensign Group holds a market capitalization near $10.2 billion, with an annualized adjusted EBITDA of $352 million in the first half of 2026, reflecting a valuation multiple of about 14.5 times EBITDA. By contrast, PACS is valued at around 11.5 times EBITDA, discounting for its ongoing legal and operational uncertainties. Based on projected adjusted EBITDA of $743 million for 2027, after accounting for net debt and legal reserves, PACS’s implied share price stands near $49.58, representing roughly 17% upside from the current $42.31. PACS’s reported net income price-to-earnings ratio is about 24.7 times, approaching Ensign’s 27 times.
Legal Investigations and Internal Control Issues Weigh on Investor Confidence
PACS is subject to multiple probes related to Medicare compliance and revenue recognition, including several Department of Justice inquiries initiated since 2024 and a Securities and Exchange Commission review of internal controls. The company acknowledged deficiencies in disclosure controls and procedures in its mid-2026 filing, with unresolved internal control weaknesses. PACS has reported refund liabilities totaling $181 million and allocated approximately $96.5 million for additional legal contingencies. These factors have maintained a cautious stance among investors, with short interest reaching 7.6% of float by mid-August. CEO Jason Murray recently sold nearly 390,000 shares under a predetermined plan but continues to hold 54.7 million shares.
Key Areas to Monitor Going Forward
Near-term performance will hinge less on additional acquisitions and more on maintaining occupancy rates above 90% in existing facilities, as well as successful integration and operational stabilization of the remaining Eduro assets. Investor focus will remain on the company’s progress in remedying internal control gaps and resolving outstanding regulatory matters. The third quarter 2026 cash flow results and upcoming financial reports will be crucial indicators of operational health and risk management. Any unexpected developments in business or legal proceedings could materially impact PACS’s valuation and market perception.
Overall, PACS Group shows measurable growth potential driven by acquisition integration and same-store improvements. However, ongoing regulatory scrutiny and internal control challenges continue to constrain its valuation, underscoring the need for close monitoring of legal developments and operational execution.